Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease

Alzheimer Disease and Associated Disorders
A Brett HauberRaymond J Townsend

Abstract

Alzheimer disease (AD) is a progressive, ultimately fatal neurodegenerative illness affecting millions of patients, families, and caregivers. Effective disease-modifying therapies for AD are desperately needed, but none currently exist on the market. Thus, accelerating the discovery, development, and approval of new disease-modifying drugs for AD is a high priority for individuals, physicians, and medical decision makers. Potentially disease-modifying drugs likely will have significant therapeutic benefits but also may have treatment-related risks. We quantified older Americans' treatment-related risk tolerance by eliciting their willingness to accept the risk of treatment-related death or permanent severe disability in exchange for modifying the course of AD. A stated-choice survey instrument was administered to 2146 American residents 60 years of age and older. On average, subjects were willing to accept a 1-year risk of treatment-related death or permanent severe disability from stroke of over 30% for a treatment that prevents AD from progressing beyond the mild stage. Thus, most people in this age cohort are willing to accept considerable risks in return for disease-modifying benefits of new AD drugs. These results are cons...Continue Reading

References

Nov 16, 2002·Archives of Neurology·Ron BrookmeyerClaudia Kawas
Mar 9, 2004·British Journal of Anaesthesia·T J GanC Chen
May 11, 2005·Archives of Neurology·Mary GanguliSteven T DeKosky
Oct 2, 2007·Journal of Women's Health·F Reed JohnsonTeresa L Kauf
Jul 1, 2006·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Stephen McConnellSteven DeKosky

❮ Previous
Next ❯

Citations

May 3, 2013·Applied Health Economics and Health Policy·A Brett HauberF Reed Johnson
Jun 16, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Jörg M FegertAxel Mühlbacher
Nov 26, 2015·Radiology·Stella K KangR Scott Braithwaite
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John F P BridgesJosephine Mauskopf
Jul 10, 2012·Epilepsy & Behavior : E&B·Ranjani ManjunathAlan B Ettinger
Apr 24, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeff J GuoDennis W Raisch
Feb 28, 2019·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Julie WatsonCharlotte Clarke
Feb 15, 2012·European Journal of Gastroenterology & Hepatology·Ateesha Farah MohamedAllan Masterson
Dec 26, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Stina SaundersCraig W Ritchie
Sep 1, 2019·Alzheimer's Research & Therapy·Jeffrey CummingsPhilip Scheltens
Jan 23, 2014·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A Brett HauberMichael Grundman
May 28, 2017·Journal of Alzheimer's Disease : JAD·Julie M Robillard, Tanya L Feng
Aug 19, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Henryk Barthel, Osama Sabri
Jun 3, 2021·International Journal of Environmental Research and Public Health·Kim EdmundsChristopher M Doran

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.